Industry perspective reveals realistic scale-up pathways for UK engineering biology investments, highlighting key commercial priorities for domestic bioplastics enterprises.
Focus on engineering biology is at the forefront of the UK government's objectives, being one of their five critical technologies (the others being quantum technologies, artifical intelligence, semiconductors, and future telecommunications), with a recent announcement of £2 billion to be invested into the field over the next 10 years. With such attention being given to engineering biology within the UK, it is critical to envisage realistic downstream channels (i.e. scale up and route to market) for this investment in order to maximise successful outcomes. This article aims to identify, from the perspective of a UK Bioplastics small and medium‐sized enterprise, areas within the scope of engineering biology that should be focused on to maximise potential for success.
No takes yet. Share an insight, caveat, or question.
Switzer et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: